Covid-19 genomic analysis reveals clusters of emerging sublineages within the delta variant

Evans K. Rono[1*, 2a,b,c]

Author details:

[1]*Independent researcher*, 10315 Berlin, Germany: *E-mail: ronoevan@gmail.com

[2]*Former staff as a:*

[a]Research Associate, LabClinic/MNB Health Lab GmbH, 14467 Potsdam, Germany;

[b]Scientific Staff, Vector Biology Unit, Max Plank Institute for Infection Biology, 10117 Berlin, Germany; and,

[c]Lecturer, Pwani University, Department of Biochemistry and Biotechnology, P.O. Box 195-80108 Kilifi, Kenya.

Abstract

The emerging SARS-CoV-2 variants may potentially have enhanced transmissibility and virulence of the virus, and impacts on performance of diagnostic tools and efficacy of vaccines. Genomic surveillance provides an opportunity to detect and characterize new mutations early enough for effective deployment of control strategies. Here, genomic data from Germany and United Kingdom were examined for genetic diversity by assessing gene mutations and inferring phylogeny. Delta variant sublineages were grouped into seven distinct clusters of spike mutations located in N-terminal domain of S1 region (T95I, D138H, *D142G, Y145H and A222V) and S2 region (T719I and *N950D). The most predominant cluster was T95I mutation, with the highest frequencies (71.1% - 83.9%) in Wales, England and Scotland, and the least frequencies (8.9% - 12.1%) in Germany. Two mutations, *D142G and *N950D here described as *reverse mutations and T719I mutation, were largely unique to Germany. In a month, frequencies of D142G had increased from 55.6% to 67.8 % in Germany. Additionally, a cluster of D142G+T719I/T mutation went up from 27.7% to 34.1%, while a T95I+ D142G+N950D/N cluster rose from 19.2% to 26.2%. Although, two distinct clusters of T95I+D138H (2.6% - 3.8%) and T95I+Y145H+A222V (2.5% - 8.5%) mutations were present in all the countries, they were most predominant in Wales and Scotland respectively. Results suggest divergent evolutionary trajectories between the clusters of D142G mutation and those of T95I mutation. These findings provide insights into underlying dynamics of evolution of the delta variant. Future studies may evaluate the epidemiological and biological implications of these sublineages.

SARS-CoV-2 (Severe acute respiratory syndrome coronavirus type 2) is a coronavirus that caused the Covid-19 disease outbreak in late 2019 in Wuhan China (Gorbalenya et al., 2020; F. Wu et al., 2020; Zhu et al., 2020). By early 2020, the disease had rapidly spread across the world and was declared a global pandemic (Cucinotta & Vanelli, 2020). Concurrently, the first Covid-19 genome from Wuhan, which became the official reference genome was published (F. Wu et al., 2020). The genome consists of around 30000 letters of single stranded positive sense RNA molecule (Jamil et al., 2021; Zhu et al., 2020). The genome codes for four structural proteins: S - spike; E - envelop; M - membrane and N - nucleoprotein, and eight non - structural proteins for RNA replication: Open reading frame (orf)1a, orf1ab; orf3a; orf6; orf7a; orf7b; orf8 and orf10 (Zhu et al., 2020).

The global spread of Covid-19 was compounded by emergence of polymorphisms in the coding sequences across its genome, which resulted in new variants of concern (VOC) (CDC, 2021a; Tegally, Wilkinson, Lessells, et al., 2021; Tegally, Wilkinson, Giovanetti, et al., 2021). Delta (B.1.617.2) variant (GISAID, 2021a) was first reported in Indian in late 2020. It spread globally and effectively outcompeted the alpha, B.1.1.7 variant (Abdool Karim & de Oliveira, 2021; CDC, 2021a; RKI, 2021; WHO, 2021b). Consequently, the delta variant became the most transmissible and virulent of all the variants that have emerged to date (Fisman & Tuite, 2021; Sheikh et al., 2021). Key amino acid mutations that define the delta variant relative to the Wuhan reference genome include: - orf1ab: P4715L, P5401L, G5063S; S: T19R, G142D, E156-, F157-, R158G, L452R, T478K, D614G, P681R, D950N; orf3a: S26L; M: I82T; orf7a: V82A, T120I; orf8: D119-, F120-; N: R203M, D377Y (CoVariants, 2021).

Genomic surveillance and open sharing of genomic data (Elbe & Buckland-Merrett, 2017) has guided the global scientific community to monitor, detect and characterize new variants (ECDC, 2021; GISAID, 2021a; Tegally, Wilkinson, Lessells, et al., 2021; Tegally, Wilkinson, Giovanetti, et al., 2021), develop vaccine (Jamil et al., 2021; WHO, 2021a), develop and continually review performance of diagnostic tools (CDC, 2021c; Wang et al., 2020) and carry out research on biological implications of the emerging mutations (Elbe & Buckland-Merrett, 2017; Tegally, Wilkinson, Lessells, et al., 2021). In addition, early detection of emerging Covid-19 mutations, is important for monitoring their prevalence and spread for prompt deployment of control measures, as well as designing experiments for assessment of efficacy of vaccines and addressing epidemiological concerns of the emerging variants (Abdool Karim & de Oliveira, 2021; ECDC, 2021).

63 Here, complete genome sequences for Covid-19 delta variant originating from Germany and
64 United Kingdom (England, Scotland, Northern Ireland and Wales) were characterized for genetic
65 diversity. First, two easier methods for retrieving coding gene sequences and for variant calling
66 directly from large datasets of unaligned SARS-CoV-2 complete genome sequences were
67 streamlined to avoid doing the computationally intensive multiple sequence alignments. These
68 methods were validated using SARS-CoV-2 genome sequences, which were downloaded from the
69 NCBI GenBank (NCBI, 2021) and the GISAID platform (GISAID, 2021b). To this end, positions
70 of the mutations in each variant were renamed with respect to positions of unaligned self
71 (individual) variant, and not relative to the reference genome (Table 1). Validated methods were
72 applied to analyze a total of 169315 SARS-CoV-2 complete genome sequences that were
73 submitted to the GISAID platform from 2021.07.23 to 2021.08.30.

74 Spike gene sequences were retrieved from the unaligned genome sequences and processed to
75 95684 high quality sequences by cleaning to remove ambiguous base calls. By exploiting the
76 spike marker mutations that define each variant, whose positions were renamed in Table 1, variant
77 calling of 13 different variants was executed. The delta variant with 92.4%, 88418 sequences, was
78 the most dominant variant (Fig.1a). The B.1.1.7 alpha variant had 1%, 991 sequences. Specific
79 positions of mutations in the delta variant were 95, 138, 142, 152, 145, and 222 (Fig.1b). A total
80 of 5547 out of 6193 sequences, which were not called to any of the 13 variants, and had been
81 categorized as 'other', were found to be of the delta variant lineage. This group of sequences had
82 key positions with mutations at 95, 142, 222, 719 and 950 (Fig. S1a), while the delta variant with
83 88418 sequences, had positions 95,138, 145 and 222 (Fig. S1b). Amino acid spike substitutions at
84 these positions were T95I, D138H, D142G, Y145H, A222V, T719I and N950D (Table S1). Of
85 these, *D142G and/or *N950D are suspected to be *reverse mutation changes from G142D and/or
86 D950N in the parental delta variant back to the wild type amino acids, which are present in the
87 Wuhan reference genome.

88 To further interrogate these amino acid substitutions, the genome sequences of the delta variant
89 were clustered into 6 main spike mutation subgroups (Table S1). The delta variant (Fig. 1b) was
90 split into five subgroups: Parental delta without T95I, Y145H and A222V mutations (n = 15324,
91 16.5%); delta with T95I mutations (n = 75307, 81.2%); delta with A222V mutations (n = 3749,
92 4%); delta with Y145H mutations (n = 1664, 1.8%); and delta with D138H mutations (n = 1314,
93 1.4%). The 'other' group (Fig.S1a) was left as a subgroup: Delta with D142G reverse mutation (n
94 = 5508, 6%). For easy of description in this study, these subgroups were designated as follows;

95 delta, delta2, delta3, delta4, delta5 and delta6 respectively (Table S1). A combination of T95I and
96 A222V spike substitutions were detected in delta2, delta4 and delta5. Delta3 with D142G reverse
97 mutations segregated further into two main subgroups with T95I and A222V mutations. Notably,
98 T719I new mutation was present in delta3. Delta6 had T95I mutation in which Y145H and A222V
99 sites were conserved.

100 To reveal the extend of mutation changes in the rest of the SARS-CoV-2 genes, similar analyses
101 were extended to all the gene coding sequences in each of the six subgroups (Table S1). All the
102 key mutations that define the parental delta variant in orf1ab, spike, orf3a, M, orf7a, and N genes
103 were present in all the delta subgroups. The orf6 protein in all the delta sequences were the most
104 conserved followed by the E protein. Orf1ab, orf10, Orf7b and N genes showed signatures of new
105 mutations. Although orf10 protein was the third most conserved gene, it showed emerging
106 mutation sites at positions L16P in delta2 and T38I in delta3 and delta5. Orf1ab had fixed
107 substitutions at positions A1306S, P2046L, P2287S, A2529V, V2930L, T3255I, T3646A and
108 A6319V. New fixed substitutions in Orf7b and N genes at positions T40I and G215C respectively
109 were observed.

110 Both orf8 and orf7a protein sequences in the reference genome, are 121 amino acid long (F. Wu et
111 al., 2020). However, orf8 and Orf7a gene sequences in these delta sublineages were characterized
112 by complex polymorphisms that included substitutions, deletions and stop codons. Some of the
113 orf8 sequences had deletions at positions G66, S67, F120 and I121, and stop codons (!) in many
114 positions such as Q18!, E19!, and E106!. Majority of orf8 sequences, had mutations at positions
115 D119I, F120! and I121T almost at the levels of fixation in the gene. In addition, orf8 had the
116 lowest sequencing coverage of its genome, which forced some sequences (n >896) to be discarded
117 from the analysis, suggesting that increasing polymorphism in this gene may be responsible for
118 the low sequencing coverage. In orf7a protein sequences, there were deletions at positions F63 and
119 V104, and stop codons in many positions including G38!, Q62!, Q90!, E91!, E92!, Q94! and E95!.

120 To check the extend of geographical spread of the individual mutations, the seven spike single
121 mutations; T95I, D138H, D142G, Y145H, A222V, T719I and N950D were mapped to their
122 respective countries (Fig. 2a). As sequencing may not be random and/or standardized across
123 nations, different nations may have under- and/or over representation of genome sequences. To
124 correct for over- and/or under representation of genome sequencies in some countries, frequencies
125 of the mutations were calculated relative to the total numbers of all the sequences coming from the
126 respective countries.

127 Delta_ D142G and delta_ N950D mutations were absent in Scotland. Delta_ N950D mutation was
128 also not detected in Northern Ireland. Delta_T95I mutations were the most prevalent mutation
129 with highest frequencies being observed in Wales (83.7%), followed by England (81%) and
130 Scotland (76.9%), while the lowest frequencies (9.1%) were observed in Germany. Interestingly,
131 the highest frequencies of the delta_ D142G (55.6%) and delta_ N950D (4.3%) 'reverse'
132 mutations as well as T719I (4.6%) were most prevalent in Germany, suggesting that these
133 mutations may be driven by selective pressures different from those of T95I mutations in England,
134 Scotland and Wales.

135 To understand genetic diversity of among these seven delta sublineages, phylogenetic clustering of
136 mutations was inferred (Fig. 2b). First, representative sequences for phylogenetic analysis were
137 selected. To do this, all the genome sequences for each of the seven groups were processed and
138 resolved to haplotype level (Table S2). From each group, the first ten sequences representing ten
139 of the most abundant haplotypes (with exception of N950D with only 4 representatives) in each
140 group were selected for phylogenetic analyses (Table S2). Results of maximum likelihood
141 phylogenetic analysis showed seven distinct clusters of mutations (Fig. 2 b). Of these, clusters of
142 delta, delta+T95I, delta+T95I+D138H, delta+T95I+Y145H+A222V mutations were detected in all
143 the five countries. Signatures of Delta+D142G+A222V+N950D/N mutations were present in
144 England, Germany and Northern Ireland. Clusters of Delta+D142G+T719I/T and
145 delta+T95I+D142G+N950D/N mutations were present in England, Germany, Northern Ireland
146 and Wales. Since the start of the pandemic, the SARS-CoV-2 has been evolving differently in
147 various jurisdictions worldwide (WHO, 2021b).

148 To track how frequencies of these mutations may have tilted over the previous one-month period,
149 similar analyses was done on a new dataset consisting of 214766 complete genome sequences
150 submitted to the GISAID platform from 31.08.2021 to 2021.09.30. Frequencies of mutations were
151 compared between the first submission (2021.07.23 and 2021.08.30) and the second submission
152 (31.08.2021 and 2021.09.30) data sets (Fig. 3a and Fig. 3b). Synonymous mutations at positions
153 163A, 410I, 856N, 1122V, 1147S and 1264V were observed (Fig. S2a). The same positions of
154 non-synonymous mutations at positions T95I, D138H, D142G, Y145H and A222V, which were
155 revealed in the first dataset, were still present in the second dataset (Fig. S2a, Fig. S2b).
156 Consistently, the T95I cluster of mutations in Wales, England, and Scotland maintained the
157 highest frequencies in the ranges between 71.2% and 80.8%. Delta+T95I+D142G+N950D/N
158 mutations in Germany had increased from 19.2% to 26.2%. In addition, Delta+D142G+T719I/T in

159 Germany had also increased from 27.7% and 34.1%. Single delta_D142G mutation, in overall,
160 increased in frequency from 55.7% (Fig. 2a) to 67.8% (Fig. S3a). In both submissions, England
161 had the highest number of sequences, while sample size from Northern Ireland in the second
162 submission suffered significantly from the lowest (N = 76) representation of sequences (Fig. S3b),
163 which was a drastic drop from 1085 sequences in the first submission (Fig. 2a).

164 These results, considering good sample sizes of genome sequences analyzed in this study, and the
165 observed wide spread of these mutations, may suggest that natural selection and not chance events
166 drives the emergence of these mutations (Lauring & Hodcroft, 2021). Mutations: T95I, D138H,
167 D142G, Y145H and A222V are clustered in the N-terminal domain (NTD) in S1 region (Fig.
168 S3b). The T719I position is located in the S2 region just before the fusion peptide, while N950D is
169 located in the central helix in the S2 domain (Lan et al., 2020) (Fig. S2b). Human neutralizing
170 antibody recognizes an epitope of the NTD suggesting that it has some immunogenic properties
171 (Chi et al., 2020; Liu et al., 2020). Mutations at spike involving T95I, was reported in Mu -
172 B.1.621 variant in Colombia, alongside other mutations located in the NTD (ins146N, Y144T and
173 Y145S), and receptor binding domain (RBD) (R346K, E484K and N501Y) and S1/S2 cleavage
174 region (P681H) mutations (Laiton-Donato et al., 2021). Many other VOC variants of interest
175 (VOI) such as Eta - B.1.525, Iota - B.1.526, also share T95I mutations (CoVariants, 2021). P681H
176 substitution was also present in B.I.1.7 alpha variant but position 145 was deleted (WHO, 2021b),
177 suggesting that positions 95 and 145 in the NTD, may be under high selective pressures.
178 Worldwide, there has been a significant reduction in frequencies of many of VOC, including the
179 B.1.1.7 alpha variant. Due to this, USA recently de-escalated their classification and definition
180 from VOC or VOI to variants being monitored (VBM) (CDC, 2021b).

181 Indeed, spike protein has been used for vaccine development (Jamil et al., 2021) because it
182 induces neutralizing antibodies (K. Wu et al., 2021). Delta variant, however, has ability to evade
183 the neutralizing antibodies (Baral et al., 2021). Delta variant mutations at T478K and L452R
184 located in RBD and P681R (Fig. S2b), enhance virus transmissibility (Starr et al., 2021).
185 Specifically, P681R mutation enhances cleavage of the protein at the S1/S2 site (Peacock et al.,
186 2021), while L452R/T478K alter conformation of the RBD (Baral et al., 2021) and enhance
187 affinity to bind to mink angiotensin-converting enzyme 2 (ACE2) receptor (Baral et al., 2021;
188 Motozono et al., 2021). Although, vaccinated people may still get infected with the delta variant,
189 vaccination prevents severe illness and critical hospitalization (Sheikh et al., 2021; Zaveri et al.,
190 2021). Mutations may increase or reduce fitness and adaptiveness (Plante et al., 2021) by

influencing its transmissibility and virulence (Lauring & Hodcroft, 2021; Li et al., 2020). Spike D614G mutation emerged during the early periods of the pandemic, and was rapidly fixed (Lauring & Hodcroft, 2021). The D614G enhances the activity of proteases at the S1/S2 cleavage site (Gobeil et al., 2021), suggesting that it works in synergy with P681R mutation to promote higher rates of virulence (Becerra-Flores & Cardozo, 2020; Korber et al., 2020) and efficiency in transmission (Hou et al., 2020). In this context, the T95I mutation being the most predominant mutation with a wide geographical spread, may suggest that it may confer more transmissive ability or fitness and/or adaptiveness to the virus (Liu et al., 2020). Evidently, the reducing frequencies of the parental delta variant observed in this survey, may be a pointer that the parental delta may soon be phased out by its emerging descendants, especially by T95I and/or *D142G mutations. These T95I and D142G mutations appear to evolve independently as seen by their clustering with D138H, Y145H+A222V, D142G+N950D/N and D142G+T719I/T. Notably, mutations in N gene and non- structural genes; orf1ab, orf3a, orf7a and orf8 genes (Table S1), revealed evident signatures of polymorphic differences, which may have some consequences in viral packaging and replication. Whether these substitutions are associated with roles of L452R/T478K and/or D614G/P681R mutations remains unknown. In addition, outstanding questions on adaptive benefits of the new mutations, and the implications they have on transmissibility, antigenicity, or virulence of the virus remain to be understood.

In summary, the unique splitting of delta variant into distinct clusters of emerging delta sub-lineages may be hypothesized to mean that the parental delta variant, may be evolving into new genetic variants. A speculation, that future research needs to test on the basis of their phenotype differences in transmissibility and/or epidemiology in real SARS-CoV-2 public health infections. These findings provide insights into the current, and possible future dynamics of evolution of the delta variant in the face of emerging sublineages under different selective pressures, including those driven by the vaccinated populace. This study was limited to assessing emergence and characterization of sublineages of the delta variant in a limited geographical region. Future research may highlight epidemiological and functional impacts of these clusters of mutations, especially the single mutations that are widespread and are increasing in frequencies and/or are persisting in the circulation.

Methods (see additional information)

1. Sample sizes and origin of SARS-CoV-2 genome sequences

2. Streamlining the retrieval of SARS-CoV-2 gene sequences

3. Easing the approach of variant calling

4. *Frequency of codons or amino acids per position*

5. *Visualizing positions of mutations*

6. Grouping of single mutations

7. Phylogenetic analysis

8. Clustering, mapping and tracking of mutations

Additional information

Methods, supplementary figures (Fig. S1, S2 and S3) and supplementary tables (Table S1 and S2) are included at end of the manuscript.

Data availability

Under terms and conditions of use, genome sequences used in this study cannot be circulated here or elsewhere. Supplementary data files: Data 1 (Fig. 1 and Fig. S1); Data 2 to data 12 (Table S1); and Data 13 (Table S2, Fig. 2, Fig. 3, Fig. S2 and Fig. S3) are provided. Any other additional data and methods are available from the author upon request.

Funding

The author did not receive any funding towards this work.

Disclosure statement

The author has no conflict of interest to disclose.

Author contributions

The author conceived the study, designed and validated the methods, downloaded and analyzed the data, prepared and submitted the manuscript.

Acknowledgements

Many thanks to all the researchers and the five Nations: England, Germany, Northern Ireland, Scotland and Wales, for investing in SARS-CoV-2 genome sequencing and openly sharing their genomic data via the GISAID platform. Great appreciation to the NCBI and the GISAID for the access of the SARS-CoV-2 genomic data.



Fig. 1 | Variant calling and revelation of positions of mutations
The total number of sequences were n = 93992, sieved from N = 169315 by removing non-DNA characters from the spike sequences. **a).** Variant-calling using the marker mutations specific to each variant of concern (VOC) in table 1. Wuhan reference sequence was included as a wild type sequence. The most dominant sequence was the delta variant. By using all the delta markers in Table1, sequences grouped under 'other', did not fall into any of the groups of the variants. **b).** Visualization of amino acid positions of the delta variant from sequences called using the deletions at 156 and 157 fixed markers for the delta variant. The variability indicates the number of different amino acid molecules competing for each position. Positions are numbered relative to the Wuhan reference sequence. Each plotted data point represents the total number of sequences sharing the most dominant amino acid in each position. The labeling threshold was placed at <99% of the total number of sequences. Positions 95, 138, 142, 145, and 222 were revealed to be accumulating mutations.



Fig. 2 | Diversity and clustering of the emerging delta sublineages
a) Mapping geographical distribution of new mutations. Sample sizes for total sequences (N) and delta variant (n) were: England (N = 80443, n = 79674); Germany (N =7128, n = 6235); Northern Ireland (N = 1115, n = 1085); Scotland (N = 5411, n = 5381); Wales (N = 1587, n = 1569) from GISAID submissions from 2021.07.23 to 2021.08.30. The frequencies were determined relative to the total number of sequences from individual country. **b)** Phylogenetic analysis. The tree shows 74 delta variant sequences representing 10 major haplotypes per group in each of the 7 groups (except N950D/N which had 4 representatives. Phylogeny was inferred using IQTREE maximum likelihood using a GTR+R6 model with 1000 rapid bootstraps (Minh et al., 2020). Two similar Wuhan reference genomes (GenBank ID: MN908947.3 and NC_045512.2) (F. Wu et al., 2020) and one previously tested delta isolate (GISAID ID: EPI_ISL_2378732) (Saito et al., 2021) were included. Seven wide spread clusters of mutations were evident from the tree.



Fig. 3 | Emergence and spread of delta clusters of mutations
a) Frequencies of cluster of mutations from the sequence batch from 2021.07.23 to 2021.08.30. Sample sizes are as listed in Fig. 2a. **b)** Frequencies of cluster of mutations from the sequence batch from 2021.08.31 to 2021.09.30. Sample sizes for total sequences (N) and delta variant (n) were: England (N = 87668, n = 87195); Germany (N =17847, n = 17596); Northern Ireland (N = 76, n = 75); Scotland (N = 13757, n = 13716); Wales (N = 5339, n = 5303). Frequencies were calculated relative to the total (N) number of sequences.

255

Table 1. Spike amino acids and positions relative to individual variant that were used as genetic markers for variant calling directly from unaligned SARS-CoV-2 complete genome sequences

1	2	3	4	5	6	7	8	9	10	11	12	13
69S	18F	417T	484K	19R	19R	19R	19R	452R	13I	5L	69S	141Y
70G	80A	484K	614G	142D	142D	142D	142D	614G	152C	95I	70G	142H
78D	215G	501Y		156G	156G	156G	156G		452R	253G	95I	143K
80P	242H			157V	157V	157V	157V		614G	477N	253G	481K
145N	243I			450R	415K	415N	450R			484K	477N	498Y
501G	244S			476T	450R	450R	476T			614G	484K	611G
611G	246L			482Q	476K	476K	482Q			701V	614G	678H
570T	414N			612G	482E	482E	612G				701V	1173F
614C	481K			679R	612G	612G	679R				888L	1089K
678H	498Y				679R	679R	948N					1098Y
681A	501G				948N	948N						
713I	611G											
716T	614C											
979A	698V											
982D	701S											
1115H												
1118F												

1 = B.1.1.7 (Alpha); **2** = B.1.351 (Beta); **3** = B.1.1.248 (P1, Gamma); **4** = P.2 (Zeta); **5** = B.1.617.1 (Kappa); **6** = B.1.617.2 (Delta); **7** = B.1.617.2 (Delta Plus); **8** = B.1.617.3; **9** = B.1.427 (Epsilon); **10** = B.1.429 (Epsilon); **11** = B.1.526 (Iota); **12** = B.1.525 (Eta); **13** = P.3 (Theta) (WHO, 2021b, 2021c). Sequences, which could not be called into any of the 13 variants were categorized as 'other' for further interrogation. The initial cases of the variants were first reported in 1 = United Kingdom, 2 = South Africa, 3 = Brazil, 4 = Brazil, 5 = India, 6 = India, 7 = India, 8 = India, 9 = USA, 10 = USA, 11 = USA, 12 = USA/Denmark, and 13 = Philippines (WHO, 2021b, 2021c).

256

References of the main manuscript

Abdool Karim, S. S., & de Oliveira, T. (2021). New SARS-CoV-2 Variants — Clinical, Public Health, and Vaccine Implications. *New England Journal of Medicine*, *384*(19), 1866–1868. https://doi.org/10.1056/NEJMC2100362

Baral, P., Bhattarai, N., Hossen, M. L., Stebliankin, V., Gerstman, B. S., Narasimhan, G., & Chapagain, P. P. (2021). Mutation-induced changes in the receptor-binding interface of the SARS-CoV-2 Delta variant B.1.617.2 and implications for immune evasion. *Biochemical and Biophysical Research Communications*, *574*, 14–19. https://doi.org/10.1016/J.BBRC.2021.08.036

Becerra-Flores, M., & Cardozo, T. (2020). SARS-CoV-2 viral spike G614 mutation exhibits higher case fatality rate. *International Journal of Clinical Practice*, *74*(8). https://doi.org/10.1111/IJCP.13525

CDC. (2021a). *Emerging SARS-CoV-2 variants*. https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/scientific-brief-emerging-variants.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fmore%2Fscience-and-research%2Fscientific-brief-emerging-variants.html

CDC. (2021b). *SARS-CoV-2 Variant Classifications and Definitions*. https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html?ACSTrackingID=USCDC_2157-DM66375&ACSTrackingLabel=CDC Updates SARS-CoV-2 Variant Classifications&deliveryName=USCDC_2157-DM66375#anchor_1632150752495

CDC. (2021c). *Why Strain Surveillance is Important for Public Health*. https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/scientific-brief-emerging-variants.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fmore%2Fscience-and-research%2Fscientific-brief-emerging-variants.html

Chi, X., Yan, R., Zhang, J., Zhang, G., Zhang, Y., Hao, M., Zhang, Z., Fan, P., Dong, Y., Yang, Y., Chen, Z., Guo, Y., Zhang, J., Li, Y., Song, X., Chen, Y., Xia, L., Fu, L., Hou, L., … Chen, W. (2020). A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. *Science (New York, N.Y.)*, *369*(6504), 650–655. https://doi.org/10.1126/science.abc6952

CoVariants. (2021). *Variant: 21A (Delta)*. https://covariants.org/variants/21A.Delta

Cucinotta, D., & Vanelli, M. (2020). WHO Declares COVID-19 a Pandemic. *Acta Bio-Medica : Atenei Parmensis*, *91*(1), 157–160. https://doi.org/10.23750/abm.v91i1.9397

ECDC. (2021). *Sequencing of SARS-CoV-2 - first update*.

https://www.ecdc.europa.eu/en/publications-data/sequencing-sars-cov-2

Elbe, S., & Buckland-Merrett, G. (2017). Data, disease and diplomacy: GISAID's innovative contribution to global health. *Global Challenges*, *1*(1), 33–46. https://doi.org/10.1002/GCH2.1018

Fisman, D. N., & Tuite, A. R. (2021). Progressive Increase in Virulence of Novel SARS-CoV-2 Variants in Ontario, Canada. *MedRxiv*, 2021.07.05.21260050. https://doi.org/10.1101/2021.07.05.21260050

GISAID. (2021a). *Delta variant*. https://www.gisaid.org/hcov19-variants/

GISAID. (2021b). *GISAID*. https://www.gisaid.org/

Gobeil, S. M. C., Janowska, K., McDowell, S., Mansouri, K., Parks, R., Manne, K., Stalls, V., Kopp, M. F., Henderson, R., Edwards, R. J., Haynes, B. F., & Acharya, P. (2021). D614G Mutation Alters SARS-CoV-2 Spike Conformation and Enhances Protease Cleavage at the S1/S2 Junction. *Cell Reports*, *34*(2).

Gorbalenya, A., Baker, S., Baric, R., de Groot, R., Drosten, C., Gulyaeva, A., Haagmans, B., Lauber, C., Leontovich, A., Neuman, B., Penzar, D., Perlman, S., Poon, L., Samborskiy, D., Sidorov, I., Sola, I., & Ziebuhr, J. (2020). The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. *Nature Microbiology*, *5*. https://doi.org/10.1038/s41564-020-0695-z

Hou, Y. J., Chiba, S., Halfmann, P., Ehre, C., Kuroda, M., Dinnon, K. H., Leist, S. R., Schäfer, A., Nakajima, N., Takahashi, K., Lee, R. E., Mascenik, T. M., Graham, R., Edwards, C. E., Tse, L. V., Okuda, K., Markmann, A. J., Bartelt, L., Silva, A. De, … Baric, R. S. (2020). SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. *Science*, *370*(6523), 1464–1468. https://doi.org/10.1126/SCIENCE.ABE8499

Jamil, S., Shafazand, S., Pasnick, S., Carlos, W. G., Maves, R., & Dela Cruz, C. (2021). Genetic variants of SARS-CoV-2: What do we know so far? *American Journal of Respiratory and Critical Care Medicine*, *203*. https://doi.org/10.1164/rccm.2021C5

Korber, B., Fischer, W. M., Gnanakaran, S., Yoon, H., Theiler, J., Abfalterer, W., Hengartner, N., Giorgi, E. E., Bhattacharya, T., Foley, B., Hastie, K. M., Parker, M. D., Partridge, D. G., Evans, C. M., Freeman, T. M., de Silva, T. I., Angyal, A., Brown, R. L., Carrilero, L., … Montefiori, D. C. (2020). Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. *Cell*, *182*(4), 812-827.e19. https://doi.org/10.1016/j.cell.2020.06.043

Laiton-Donato, K., Franco-Muñoz, C., Álvarez-Díaz, D. A., Ruiz-Moreno, H. A., Usme-Ciro, J. A., Prada, D. A., Reales-González, J., Corchuelo, S., Herrera-Sepúlveda, M. T., Naizaque, J.,

Santamaría, G., Rivera, J., Rojas, P., Ortiz, J. H., Cardona, A., Malo, D., Prieto-Alvarado, F., Gómez, F. R., Wiesner, M., … Mercado-Reyes, M. (2021). Characterization of the emerging B.1.621 variant of interest of SARS-CoV-2. *Infection, Genetics and Evolution*, *95*, 105038. https://doi.org/10.1016/J.MEEGID.2021.105038

Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q., Zhang, L., & Wang, X. (2020). Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. *Nature*, *581*(7807), 215–220. https://doi.org/10.1038/S41586-020-2180-5

Lauring, A., & Hodcroft, E. (2021). Genetic Variants of SARS-CoV-2—What Do They Mean? *JAMA*, *325*. https://doi.org/10.1001/jama.2020.27124

Li, Q., Wu, J., Nie, J., Zhang, L., Hao, H., Liu, S., Zhao, C., Zhang, Q., Liu, H., Nie, L., Qin, H., Wang, M., Lu, Q., Li, X., Sun, Q., Liu, J., Zhang, L., Li, X., Huang, W., & Wang, Y. (2020). The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity. *Cell*, *182*(5), 1284-1294.e9. https://doi.org/10.1016/j.cell.2020.07.012

Liu, L., Wang, P., Nair, M. S., Yu, J., Rapp, M., Wang, Q., Luo, Y., Chan, J. F.-W., Sahi, V., Figueroa, A., Guo, X. V, Cerutti, G., Bimela, J., Gorman, J., Zhou, T., Chen, Z., Yuen, K.-Y., Kwong, P. D., Sodroski, J. G., … Ho, D. D. (2020). Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. *Nature*, *584*(7821), 450–456. https://doi.org/10.1038/s41586-020-2571-7

Minh, B. Q., Schmidt, H. A., Chernomor, O., Schrempf, D., Woodhams, M. D., von Haeseler, A., & Lanfear, R. (2020). IQ-TREE 2: New Models and Efficient Methods for Phylogenetic Inference in the Genomic Era. *Molecular Biology and Evolution*, *37*(5), 1530–1534. https://doi.org/10.1093/molbev/msaa015

Motozono, C., Toyoda, M., Zahradnik, J., Saito, A., Nasser, H., Tan, T. S., Ngare, I., Kimura, I., Uriu, K., Kosugi, Y., Yue, Y., Shimizu, R., Ito, J., Torii, S., Yonekawa, A., Shimono, N., Nagasaki, Y., Minami, R., Toya, T., … Sato, K. (2021). SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity. *Cell Host & Microbe*, *29*(7), 1124-1136.e11. https://doi.org/10.1016/J.CHOM.2021.06.006

NCBI. (2021). *NCBI*. https://www.ncbi.nlm.nih.gov/

Peacock, T. P., Sheppard, C. M., Brown, J. C., Goonawardane, N., Zhou, J., Whiteley, M., Consortium, P. V., Silva, T. I. de, & Barclay, W. S. (2021). The SARS-CoV-2 variants associated with infections in India, B.1.617, show enhanced spike cleavage by furin. *BioRxiv*, *44*(0), 2021.05.28.446163. https://www.biorxiv.org/content/10.1101/2021.05.28.446163v1%0Ahttps://www.biorxiv.org/content/10.1101/2021.05.28.446163v1.abstract

Plante, J. A., Liu, Y., Liu, J., Xia, H., Johnson, B. A., Lokugamage, K. G., Zhang, X., Muruato, A. E., Zou, J., Fontes-Garfias, C. R., Mirchandani, D., Scharton, D., Bilello, J. P., Ku, Z., An, Z., Kalveram, B., Freiberg, A. N., Menachery, V. D., Xie, X., … Shi, P. Y. (2021). Spike mutation D614G alters SARS-CoV-2 fitness. *Nature*, *592*(7852), 116–121. https://doi.org/10.1038/S41586-020-2895-3

RKI. (2021). *Bericht zu Virusvarianten von SARS-CoV-2 in Deutschland, insbesondere zur Variant of Concern (VOC) B.1.1.7*. rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/DESH/Bericht_VOC_2021-03-17.pdf?__blob=publicationFile

Saito, A., Nasser, H., Uriu, K., Kosugi, Y., Irie, T., Shirakawa, K., Sadamasu, K., Kimura, I., Ito, J., Wu, J., Ozono, S., Tokunaga, K., Butlertanaka, E. P., Tanaka, Y. L., Shimizu, R., Shimizu, K., Fukuhara, T., Kawabata, R., Sakaguchi, T., … Sato, K. (2021). SARS-CoV-2 spike P681R mutation enhances and accelerates viral fusion. *BioRxiv*, 2021.06.17.448820. https://doi.org/10.1101/2021.06.17.448820

Sheikh, A., McMenamin, J., Taylor, B., & Robertson, C. (2021). SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. In *Lancet (London, England)* (Vol. 397, Issue 10293, pp. 2461–2462). https://doi.org/10.1016/S0140-6736(21)01358-1

Starr, T. N., Greaney, A. J., Dingens, A. S., & Bloom, J. D. (2021). Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016. *Cell Reports Medicine*, *2*(4), 100255. https://doi.org/10.1016/J.XCRM.2021.100255

Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., Mlisana, K., von Gottberg, A., Walaza, S., Allam, M., Ismail, A., Mohale, T., Glass, A. J., Engelbrecht, S., Van Zyl, G., … de Oliveira, T. (2021). Detection of a SARS-CoV-2 variant of concern in South Africa. *Nature*, *592*(7854), 438–443. https://doi.org/10.1038/S41586-021-03402-9

Tegally, H., Wilkinson, E., Lessells, R. J., Giandhari, J., Pillay, S., Msomi, N., Mlisana, K., Bhiman, J. N., von Gottberg, A., Walaza, S., Fonseca, V., Allam, M., Ismail, A., Glass, A. J., Engelbrecht, S., Van Zyl, G., Preiser, W., Williamson, C., Petruccione, F., … de Oliveira, T. (2021). Sixteen novel lineages of SARS-CoV-2 in South Africa. *Nature Medicine*, *27*(3), 440–446. https://doi.org/10.1038/s41591-021-01255-3

Wang, R., Hozumi, Y., Yin, C., & Wei, G. W. (2020). Mutations on COVID-19 diagnostic targets. *Genomics*, *112*(6), 5204–5213. https://doi.org/10.1016/J.YGENO.2020.09.028

WHO. (2021a). *The effects of virus variants on COVID-19 vaccines*. https://www.who.int/news-room/feature-stories/detail/the-effects-of-virus-variants-on-covid-19-vaccines?gclid=CjwKCAjw-sqKBhBjEiwAVaQ9azeXfBJUkJAMRUAYSG-Z9mQziqRWzpkDVBD8-wFLoykiLqqng0YBCBoCKN0QAvD_BwE

WHO. (2021b). *Tracking SARS-CoV-2 variants*. https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/

WHO. (2021c). *WHO announces simple, easy-to-say labels for SARS-CoV-2 Variants of Interest and Concern*.

Wu, F., Zhao, S., Yu, B., Chen, Y. M., Wang, W., Song, Z. G., Hu, Y., Tao, Z. W., Tian, J. H., Pei, Y. Y., Yuan, M. L., Zhang, Y. L., Dai, F. H., Liu, Y., Wang, Q. M., Zheng, J. J., Xu, L., Holmes, E. C., & Zhang, Y. Z. (2020). A new coronavirus associated with human respiratory disease in China. *Nature*, *579*(7798), 265–269. https://doi.org/10.1038/S41586-020-2008-3

Wu, K., Werner, A. P., Moliva, J. I., Koch, M., Choi, A., Stewart-Jones, G. B. E., Bennett, H., Boyoglu-Barnum, S., Shi, W., Graham, B. S., Carfi, A., Corbett, K. S., Seder, R. A., & Edwards, D. K. (2021). mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. *BioRxiv*, 2021.01.25.427948. https://doi.org/10.1101/2021.01.25.427948

Zaveri, L., Singh, R., Basu, P., Banu, S., Mukherjee, P., Vishwakarma, S., Sahni, C., Kaur, M., Singh, N. K., Yadav, A. K., Yadav, A. K., Ashish, Mishra, S., Tiwari, S., Mishra, S. P., Vodapalli, A., Bollu, H., Das, D., Singh, P. P., … Tallapaka, K. B. (2021). Genomic analysis of SARS-CoV-2 breakthrough infections from Varanasi, India. *MedRxiv*, 2021.09.19.21262487. https://doi.org/10.1101/2021.09.19.21262487

Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., Niu, P., Zhan, F., Ma, X., Wang, D., Xu, W., Wu, G., Gao, G. F., & Tan, W. (2020). A Novel Coronavirus from Patients with Pneumonia in China, 2019. *New England Journal of Medicine*, *382*(8), 727–733. https://doi.org/10.1056/NEJMoa2001017

Additional Information

Methods and supplementary figures and tables

Methods

1. Sample size and origin of SARS-CoV-2 genome sequences

A total of 169315 complete SARS-CoV-2 genome sequences from Germany and United Kingdom that were submitted to the GISAID platform from 2021.07.23 to 2021.08.30, and a subsequent, 214766 latest genome sequences, which were submitted from 2021.08.31 to 2021.09.30 were downloaded for analysis in this study from the GISAID platform /) on 2021.08.30 and 2021.09.30 respectively (https://www.gisaid.org. These nations and their respective research communities are among the geographical regions, which have invested in genomic surveillance as part of their routine monitoring of the SARS-CoV-2, hence their genomic data are reliable in estimating the actual Covid-19 circulation in their respective territories (GOV.UK, 2021; RKI, 2021). The downloaded sequences were read to v4.1.1 R software (Team, 2021) using the readDNAStringSet function of v2.60.2 Biostrings R package (H. Pagès, P. Aboyoun, 2021). DECIPHER R package v2.20.0 (Erik, 2016) was used to Browse and align the sequences.

2. Streamlining the retrieval of SARS-CoV-2 gene sequences

To streamline a faster and easier method to retrieve gene sequences without doing computationally intensive process of SARS-CoV-2 sequence alignments of large sequence datasets with respect to the Wuhan NC_045512 reference genome, patterns of short (between 8 and 40 bases) sequences flanking all the genes, similar length ranges for patterns at the start of the genes, and similar length ranges for patterns at the end of the genes were identified from the Wuhan reference genome (Wu et al., 2020). The patterns specific and/or not specific to spike gene were used to trim off the spike gene regions out of the DNA string sets of the genome sequences using the sub function of R Documentation. For example:

To trim off the flanking region and keep gene sequences but excluding the two patterns, which are not part of the spike gene, a code like this was used;

```
S <- DNAStringSet(sub(".*ACAACTAAACGAACA(.*?)TAAACGAACTTAT.*", "\\1", S))
```

To trim off the flanking regions and keep gene sequences including the two patterns because they are part of the spike gene, a code similar to this was used:

```
S <- DNAStringSet(sub(".*(ATGTTTGTTTTTCTTGT.*?TCAAATTACATTACACA).*", "\\1", S))
```

To trim off the flanking regions and keep gene sequences including the first pattern, which is part of the gene, while at the same time discarding the second pattern, which is not part of the coding gene sequences, a code like this was used;

```
S <- DNAStringSet(sub(".*(ATGTTTGT.*)TAAACGAACT.*","\\1", S))
```

Note that a number of different patterns were selected to capture all the sequences, especially gene sequences with unambiguous nucleotide mutations in regions that match the selected pattern. To clarify this, a few selected sequences, in which the used patterns did not capture the gene due to mutations, were filtered and selected for alignment with the complete genome of Wuhan reference sequence. To inspect and identify additional patterns required to capture all the sequences, the results of sequence alignment were browsed in the browser.

```
S <- S[width(S) >3819,]
S <- DNAStringSet(c(ref,S))
Salign <- AlignSeqs(S)
BrowseSeq(Salign, highlight = 1)
```

The genomic range of the spike gene of the Wuhan reference genome were used to locate and analyze the spike genes from the sequences as follows:

```
refS <- DNAStringSet(substr(ref, start=21563, stop=25384))
Salign2 <- DNAStringSet(substr(Salign, start=21563, stop=25384))
```

Adjustment on this range was made to include immediate flanking regions of the alignment so that presence of mutations in the flanking regions that render the trimming of the spike gene a failure was inspected. Using blindly downloaded SARS-CoV-2 complete genome sequences from the GISAID platform and the NCBI GenBank (GISAID, 2021; NCBI, 2021), all possible patterns were validated for trimming genome sequences and retrieving the spike gene sequences without having to do multiple sequence alignments. To this end, the spike gene sequences were successfully retrieved from thousand complete genomic sequences. Width function was used to assess the efficiency of trimming and to check variations in lengths of the retrieved spike gene sequence

```
all_S1 <- all_S[!width(all_S) >3813,]
all_S2 <- all_S[!width(all_S) ==3813,]
all_S3 <- all_S[width(all_S) ==3813,]
all_S4 <- all_S[!width(all_S) <3813,]
```

3. Easing the approach of variant calling

Next, a method for variant calling was also simplified. To do this, the workflow for variant calling was done by numbering positions of the spike mutation markers that define individual variants relative to self, instead of the reference spike sequence (Table 1). The retrieved spike sequences were processed by cleaning to remove non-nucleotide characters using clean function of v1.50.0 ShortRead R package (Morgan et al., 2009).

Cleaned sequences were translated to protein amino acid sequences using translate function of Biostrings R package (H. Pagès, P. Aboyoun, 2021). The strings of amino acid sequences were processed for calling the variants in data frame format, where all the strings of sequences should subsequently be split into individual amino acid letters. Before converting them to data frame, all the sequences were made to have the same lengths. Edges from the ends of all the sequences regions were slightly trimmed to retain 1 to 1195, effectively forcing them to have same lengths. This range was chosen because all the positions for calling the variants were within this range (Table 1). This was done using substr function of R Documentation.

```
Sa <- AAStringSet(substr(Sa, start=1, stop=1195)).
```

The trimmed sequences were subsequently transformed to data frame dataset. To get individual amino acid characters in their respective positions, stringsets of amino acid were split using stri_extract_all_regex function of v1.7.4 stringi R package (Gagolewski, 2021).

For amino acid, at protein level:

```
dfSa   <- data.frame(stri_extract_all_regex(dfSa$Sa, '.{1,1}'))
```

For codon, at nucleotide level:

```
dfSc   <- data.frame(stri_extract_all_regex(dfSc$Sc, '.{1,3}'))
```

To call the variants by exploiting the positions of the amino acid from the split amino acid stringsets, key genetic markers specific to each variant (Table 1), were used. For example, below is the code, which was used to call the parental delta variant;

```
dfSa$B.1.617.2_Delta <- ifelse(dfSa$X19=="R" &dfSa$X142=="D" &
dfSa$X156=="G&dfSa$X157=="V"&dfSa$X415=="K"&dfSa$X450=="R"&
dfSa$X476=="K" & dfSa$X482=="E"& dfSa$X612=="G"& dfSa$X679=="R"&
dfSa$X948=="N" ,"yes", "no")
```

This was repeated for each individual variant named in Table 1. Sequences which could not be classified into any of the variants were categorized as ‘other’ for further interrogation.

Data were processed further using v1.4.4 reshape2 (Wickham, 2007), v1.14.0 data.table (Srinivasan, 2021), v1.3.1 tidyverse (Wickham et al., 2019), v1.1.3 tidyr (Wickham, 2021), v0.6.5 xlsx(Arendt, 2020), and v1.4.0 writexl R packages. Plots were visualized using v3.3.5 ggplot2 R

package (H, 2016) and v0.4.13 circlize R package (Gu et al., 2014). Plots were further refined in v1.1.1 Inkscape (Project, 2021).

4. *Frequency of codons or amino acids per position*

To summarize frequency matrix of codons or amino acids per position in all the gene sequences, the excised sequences from the complete genomes were analyzed both at the codon and the amino acid levels. Delta spike protein sequences have protein lengths of 1271 amino acids, which are characterized by two key fixed deletion mutations of two codons (amino acids) in the positions between 156 and 158 (See comment* for explanation below the Table S1). The sequences were transformed to data frame and split to positions 1 to 1271 of individual amino acids. Note that these sequences were not aligned relative to the Wuhan reference genome, and as such they were two-amino acid shorter in lengths than the reference genome. To make them have a full-size of 1273 amino acid long equivalent to the positions in the reference genome, 2 instances of gaps "-" both at the codon and the amino acid levels were introduced into each sequence at positions 156 and 157 in the data frame of the sequences. This was done as follows:

```
Sa$"156" <- "-"
Sa$"157" <- "-"
Sa<- Sa[, c(1:155,1272,1273,156:1271)]
Sa <- data.frame(t(Sa))
rownames(Sa) <-1:1273
Sa <- data.frame(t(Sa))
```

To enable visualization of positions with mutations, the split positions were transformed by transposing the rows (sequences) to columns, which in turn made the columns (amino acid positions) as rows:

```
Sa <- data.frame(t(Sa))
```

This offered an opportunity to count in a row wise the codons (nucleotide level) and amino acids (protein level) competing for each individual position across all the sequences. To do this, unite function of v1.0.7 dplyr R package (Hadley Wickham, Romain François & Henry, 2021) was used to unite the rows (codons or amino acids) with commas as separators.

For instance, considering 180000 as the number of sequences to be analyzed, the unite code would look like this:

```
Sdelta   <- unite(Sdelta, "seq", c("X1":"X180000"), sep = ",")
```

To count the frequencies of individual codons or amino acids across all the sequences present per position, a code below was used:

```
Freq.Sdelta   <-  cbind(Sdelta, as.data.frame.matrix(
  +   table(
    stack(
      setNames(
        strsplit(as.character(Sdelta$seq), ','), 1:nrow(Sdelta))
    )[2:1])))
Freq.Sdelta$seq = NULL
Freq.Sdelta <- as.data.frame(Freq.Sdelta)
```

5. *Visualizing positions of mutations*

To count the number of codons or amino acids competing for an individual position, a new column was introduced to the above Freq.Sdelta data frame as follows:

```
Freq.Sdelta$Variability  <- rowSums(Freq.Sdelta!=0)
```

For a conserved codon or amino acid in a given position, in a total of 180000 sequences, it is expected that all the 180000 sequences will have same codon or amino acid at this position. However, if there is a synonymous or non-synonymous mutation at codon level, the maximum number of sequences, in this case 180000, will be shared by the wild type codon and the new codon bearing a mutation. At the amino acid level, only non-synonymous mutation will compete for the position, effectively reducing the total number of 180000 sequences from the wild type amino acid. As a consequence of this, no position will have the maximum counts amino acids as 180000 of sequences. To show the most predominant codon and/or amino acid in each position, which in this case will have highest maximum number of sequences in each position, new column was introduced by running the following code:

```
Freq.Sdelta$Max_n <- apply(Freq.Sdelta, 1, max)
```

To enable visualization in a graph indicating position of the sequence, a new variable ‘Position’ in the last column was introduced as:

```
Freq.Sdelta$Position <- 1:1273
```

Positions of codons or amino acids, were visualized in a plot showing the number of sequences ‘Max_n’ against the position ‘Position’ in the sequence with ‘variability’ using ggplot2 R package. To reveal sites that are undergoing mutations, sites with threshold of <99% of the sequences were labelled. Note that this graph neither showed nor discriminated between the fixed

mutations and the conserved sites in the gene. To interrogate amino acid sites that have fixed mutations and/or are undergoing fixation in the spike sequences (all_Sa) relative to the NC_045512 reference sequence, the Wuhan wild-type genome was included as the first sequence in the amino acid sequences dataset. The sequences were browsed using the BrowseSeq function of DECIPHER R package as mentioned above, while highlighting the reference gene.

```
BrowseSeq(all_Sa, highlight = 1)
```

In the final dataset, the reference gene sequences for codons and/or amino acids were included for comparison with the codons and/or amino acids in the sequences. For codon frequency, codons used in the sequences were translated to show their respective amino acids, so that synonymous and non-synonymous codons can easily be identified.

To observed genetic diversity in the remaining genes: Orf1ab, orf3a, E, M, orf6, orf7a, orf7b, orf8, N and orf10, similar analyses that were done on the spike gene were extended to all these genes. Note that for the orf1ab gene, the reading was corrected so that part orf1a of the gene joins with the second part orf1b to give the correct reading frame for the entire orf1ab gene. Therefore, reading frame of orf1ab gene in all the orf1ab sequences was corrected by running the following code:

```
all_orf1ab <- DNAStringSet(str_replace (all_orf1ab, "AAACGGGTT", "AAACCGGGTT"))
```

6. Grouping of single mutations

Sequences were grouped into groups with different single non-synonymous mutations using the genetic markers for the delta variant in Table 1 as well as new emerging single amino acid mutations. By looking at the patterns of these new single mutations at the spike protein sequences, and to some extend the rest of the genes, further groups consisting of clusters of one or more combinations of mutations were created, and confirmed by phylogenetic analysis.

7. Phylogenetic analysis

To select representative genomes from 93647 sequences (GISAID submissions from 2021.07.23 to 2021.08.30) for use to infer phylogeny, complete genome sequences were trimmed. The sequences were trimmed to exclude the sequence portions before the first gene (orf1ab) and the sequence portions after the last gene (orf10) using the previously described pattern matching method above. Sequences were cleaned to ensure quality of sequence coverage on the entire genome. Frequency of identical genomes (haplotypes) were counted from the trimmed sequences, and those sequences which appeared once were discarded to remain with 27993 genomes. Frequencies of haplotypes in each mutation category were counted and arranged from the most

172 dominant to the least dominant haplotypes. From these grouped haplotypes, representative
173 sequence for each of the first 10 haplotypes per mutation category (except for delta_ N950D,
174 which had only 4 representatives), were used to infer phylogeny (Table S2).
175 Phylogeny was inferred using IQTREE maximum likelihood (Minh et al., 2020)
176 (http://iqtree.cibiv.univie.ac.at/) applying a GTR+R6 model with 1000 rapid bootstraps. Two
177 similar Wuhan reference genomes (GenBank ID: MN908947.3 and NC_045512.2) (Wu et al.,
178 2020) and previously tested delta isolate (GISAID ID: EPI_ISL_2378732) (Saito et al., 2021)
179 were included in the analysis to assess the extent of genetic divergence. Phylogeny annotations,
180 including geographic distributions of clusters of mutations were done using v3.1.4.991 ggtree R
181 package (Yu, 2020).

182 *8. Clustering, mapping and tracking of mutations*

183 Beyond the haplotypes, clusters of mutations were retraced back to the whole dataset to confirm
184 the divergence of emerging delta sublineages. These clusters of mutations were mapped to their
185 respective countries, which the sequences originated from. To detect changes in frequencies of
186 clusters of mutations that had been identified, the most recent set of genomic data (N = 214766)
187 submitted to the GISAID platform from the same countries in the previous month from
188 2021.08.31 to 2021.09.30, were downloaded on 2021.09.30 and analysed in a similar way as
189 described above. Results were compared with those of genome sequences (N = 169315) from the
190 submissions of the period from 2021.07.23 to 2021.08.30.
191

Supplementary figures and tables



Fig. S1 | Resolving sublineages of the delta variant at positions of mutations
a). Revealing positions of mutations, from the 'other' group in Fig. 1a. The delta variant deletion mutations at positions 156 and 157 were used as conserved markers. Positions 95, 142, 222, 719 and, 950 were revealed as the main hotspot sites for mutations. The total number of sequences were n = 5547. Out of these, 5242 and 370 sequences had *reverse mutations at positions *G142D and *N950D respectively. The rest of the mutations in all the sequences within the 'other' delta group were the typical mutations of the delta variant. **b).** Position of mutations in the delta variant sequences called using all the key marker mutations present in the parental delta variant. Positions 95, 138, 145, and 222 were also observed to be selective pressures for mutations. The total number of sequences were n = 88418. Variability is as was defined in Fig. 1b.



Fig. S2 | Synonymous and non-synonymous mutations in the delta sublineages
a). Revealing positions of mutations at codon level, from the sequence batch submitted from 2021.08.31 to 2021.09.30. Positions 163, 410, 856, 1122 and 1147 are synonymous mutations. The rest of the labelled positions were non-synonymous mutations, which included position 5. **b).** Non-synonymous mutations cluster at the NTD. The total number of the delta sequences were n = 123867. The inset on top shows a schematic representation of spike protein showing domains (Lan et al., 2020) and approximate positions in the graph: N-terminal domain; NTD, receptor binding domain; RBD, receptor binding motif; RBM, subdomain 1; SD1, subdomain 2; SD2, fusion peptide; FP, heptad repeat 1; HR1, central helix; CH, connector domain; CD, heptad repeat 1; heptad repeat 2; HR2, cytoplasmic tail; CT. Variability is as was defined before.

196



Fig. S3 | Distributions of single and clusters of mutations
a) Frequencies of single delta mutations from the sequence batch from 2021.08.31 to 2021.09.30. Sample sizes are as listed in Fig. 3b. **b)** Frequencies of cluster of mutations from the sequence submission batch of from 2021.08.31 to 2021.09.30. Sample sizes are as listed in Fig. 3b. Frequencies were calculated relative to the total (N) number of sequences.

197

Table S1. Amino acid mutations in all coding sequences of 6 groups of delta sublineages

Protein (Length)	Delta key mutations	Delta (16.5%) n = 15324	Delta2 +T95I (81.2%) n = 75307	Delta3 +D142G (6%) n = 5508	Delta4 +A222V (4%) n = 3749	Delta5 +Y145H (1.8%) n = 1664	Delta6 +D138H (1.4%) n = 1314
Spike (1271)	T19R G142D *E156- *F157- *R158G L452R T478K D614G P681R D950N	T19R G142D E156- F157- R158G L452R T478K D614G P681R D950N T22T/I P251P/L D1127D/G A67A/V I1115I/V G1219G/V	T19R G142D E156- F157- R158G L452R T478K D614G P681R D950N T95I D138D/H Y145Y/H A222A/V P1162P/S	T19R D142G E156- F157- R158G L452R T478K D614G P681R D950N/D T29T/A T95T/I A222A/V T250T/I P251P/L T719T/I L5L/F R21R/T H66H/Y G181G/V D253D/A I850I/L D979D/E G1167G/V	T19R G142D E156- F157- R158G L452R T478K D614G P681R D950N A222V V36V/F T95T/I Y145Y/H V1264V/L L5L/F R21R/T D253D/A D979D/E	T19R G142D E156- F157- R158G L452R T478K D614G P681R D950N Y145H T95I A222V V36V/F L5L/F V1264V/L	T19R G142D E156- F157- R158G L452R T478K D614G P681R D950N D138H T95I L5L/F A522A/S T827T/I I1114I/T T29T/A T547T/I T1120T/I G1124G/V
Orf1ab (7096)	P4715L P5401L G5063S	P4715L P5401L G5063S A1306S P2046L P2287S V2930L T3255I T3646A A6319V E87E/D K261K/N D691D/N L5230L/I E5689E/D	P4715L P5401L G5063S A1306S P2046L P2287S V2930L T3255I T3646A A6319V A2529V V665V/I G661G/S T814T/I E1909E/A S2048S/F V2766V/F L3606L/F H5005H/Y D5271D/N/Y	P4715L P5401L G5063S A1306S P2046L P2287S V2930L T3255I T3646A A6319V E87E/D K261K/N P309P/L V665V/I P1640P/L E1724E/D A2529A/V A3209A/V L3606L/F V3718V/A T3750T/I R4589R/Q D5216D/Y L5230L/I T5941T/I K6958K/R	P4715L P5401L G5063S A1306A/S P1640L P2046P/L P2287P/S A2529A/V V2930V/L A3209V V3718A T3750I A6319A T708T/I T2906T/I T3255T/A Y3502Y/C T3646T/A T4161T/I R4589R/Q T5941T/I D6249D/Y R7014R/N	P4715L P5401L G5063S A1306S P2046L P2287S A2529V V2930L T3255I T3646A A6319V M5900M/I R7014R/N	P4715L P5401L G5063S A1306S P2046L P2287S A2529V V2930L T3255I T3646A A6319V I695I/V T1168T/I S1520S/F Y1859Y/H L2329L/F A3392A/V L3606L/F V3690V/L K3832K/T P4624P/S
ORF3a (275)	S26L	S26L A99A/V S180S/F	S26L K235K/T	S26L K16K/T D27D/Y V88V/L K235K/T	S26L A23A/S L83L/F S171S/L	S26L	S26L K16K/N K66K/I

Table S1. Amino acid mutations in all coding sequences of 6 groups of delta sublineages

Protein (Length)	Delta key mutations	Delta (16.5%) n = 15324	Delta2 +T95I (81.2%) n = 75307	Delta3 +D142G (6%) n = 5508	Delta4 +A222V (4%) n = 3749	Delta5 +Y145H (1.8%) n = 1664	Delta6 +D138H (1.4%) n = 1314
E (75)	-	-	-	V58F	-	-	-
M (222)	I82T	I82T	I82T	I82T	I82T A2A/S	I82T	I82T
Orf6 (61)	-	-	-	-	-	-	-
Orf7a (121)	V82A T120I	V82A T120I V24V/F P45P/L C58C/F A79A/D L116L/F	V82A T120I H73H/Y	V82A T120I P45P/L L116L/F R118R/G	V82A T120I L112L/I	V82A T120I	V82A T120I G38G/E
Orf7b (43)		T40I H42H/S A43A/P	T40I	T40I/T	T40T/I	T40I	T40I
Orf8 (121) (120) (119)	D119- F120-	D119I F120stop I121T V33V/F A65A/S	D119I F120stop I121T S67S/F	D119I F120stop I121T A65A/S R115R/C	D119I F120stop I121T	D119I F120stop I121T	D119I F120stop I121T
N (419)	D63G R203M D377Y	D63G R203M D377Y G215C Q9Q/L S327S/L G96G/C G238G/C P383P/S D402D/Y	D63G R203M D377Y G215C	D63G R203M D377Y G215C Q9Q/L R209R/I M210M/E S327S/L W330W/L	D63G R203M D377Y G215G/C S202S/I R209R/I M210M/S	D63G R203M D377Y G215C A55A/S S202S/I	D63G R203M D377Y G215C S327S/L
Orf10 (38)	-	-	L16L/P	T38T/I	-	T38T/I	-

Bright green colour highlights fixed mutations. Turquoise colour highlights new substitutions undergoing fixation. Grey colour shows emerging reverse-mutations. Yellow colour represents mutations that have significantly increased in frequencies. The rest substitutions (not highlighted) are candidates for future genomic surveillance. Cut off for highlighting was placed at >1% prevalence, that is, more than 1 sequence in every 100 sequences sharing same mutation per site. '/' for example, in T22T/I, means that the site has two amino acids, but in this case, there are more 'T's than 'I's. *These three positions can also be captured in these two ways: Either as deletions at F157- and R158-, and substitution at E156G or deletions at E156- and R158-, and substitution at F157G. In all three cases, the final markers that define an unaligned delta variant sequence at these positions are 156G and 157V, and therefore they have no effect on variant calling.

198
199

Table S2. Resolving the genome sequences into clusters of haplotypes in each delta lineage

Order of haplotype dominance	Frequency of Spike delta haplotypes per mutation							
	Delta	Delta + T95I	Delta + D138H	Delta + D142G	Delta + Y145H	Delta + A222V	Delta + T719I	Delta + N950D
1st	215	401	36	54	188	188	54	2
2nd	123	188	34	37	33	33	16	1
3rd	102	187	30	25	24	28	4	1
4th	96	146	21	21	21	28	3	1
5th	87	131	20	20	21	24	3	NA
6th	67	127	16	18	18	23	3	NA
7th	63	122	13	18	15	21	2	NA
8th	52	103	10	16	14	21	2	NA
9th	47	84	10	15	14	18	2	NA
10th	41	83	10	13	9	16	1	NA

References for Methods

Arendt, A. D. and C. (2020). *Read, Write, Format Excel 2007 and Excel 97/2000/XP/2003 Files. R package version 0.6.5.*

Erik, S. (2016). Using DECIPHER v2.0 to Analyze Big Biological Sequence Data in R. *The R Journal*, *8*, 352. https://doi.org/10.32614/RJ-2016-025

Gagolewski, M. (2021). *stringi: Fast and portable character string processing in R_. R package version 1.7.4*. https://stringi.gagolewski.com/

GISAID. (2021). *GISAID*. https://www.gisaid.org/

GOV.UK. (2021). *Investigation of SARS-CoV-2 variants of concern: technical briefings*. https://www.gov.uk/government/publications/investigation-of-novel-sars-cov-2-variant-variant-of-concern-20201201

Gu, Z., Gu, L., Eils, R., Schlesner, M., & Brors, B. (2014). circlize implements and enhances circular visualization in R . *Bioinformatics*, *30*(19), 2811–2812. https://doi.org/10.1093/bioinformatics/btu393

H. Pagès, P. Aboyoun, R. G. and S. D. (2021). *Biostrings: Efficient manipulation of biological strings. R package version 2.60.2*.

H, W. (2016). ggplot2: Elegant Graphics for Data Analysis. Springer-Verlag New York, 2016. *Springer-Verlag New York.*

Hadley Wickham, Romain François, L., & Henry, K. M. (2021). *dplyr: A Grammar of Data Manipulation. R package version 1.0.7.*

Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q., Zhang, L., & Wang, X. (2020). Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. *Nature*, *581*(7807), 215–220. https://doi.org/10.1038/S41586-020-2180-5

Minh, B. Q., Schmidt, H. A., Chernomor, O., Schrempf, D., Woodhams, M. D., von Haeseler, A., & Lanfear, R. (2020). IQ-TREE 2: New Models and Efficient Methods for Phylogenetic Inference in the Genomic Era. *Molecular Biology and Evolution*, *37*(5), 1530–1534. https://doi.org/10.1093/molbev/msaa015

Morgan, M., Anders, S., Lawrence, M., Aboyoun, P., Pagès, H., & Gentleman, R. (2009). ShortRead: a bioconductor package for input, quality assessment and exploration of high-throughput sequence data. *Bioinformatics*, *25*(19), 2607–2608. https://doi.org/10.1093/bioinformatics/btp450

NCBI. (2021). *NCBI*. https://www.ncbi.nlm.nih.gov/

Project, I. (2021). *Inkscape*. https://inkscape.org

RKI. (2021). *MF 2: Genome Sequencing and Genomic Epidemiology*. https://www.rki.de/EN/Content/Institute/DepartmentsUnits/MF/MF2/mf2_node.html

Saito, A., Nasser, H., Uriu, K., Kosugi, Y., Irie, T., Shirakawa, K., Sadamasu, K., Kimura, I., Ito, J., Wu, J., Ozono, S., Tokunaga, K., Butlertanaka, E. P., Tanaka, Y. L., Shimizu, R., Shimizu, K., Fukuhara, T., Kawabata, R., Sakaguchi, T., … Sato, K. (2021). SARS-CoV-2 spike P681R mutation enhances and accelerates viral fusion. *BioRxiv*, 2021.06.17.448820. https://doi.org/10.1101/2021.06.17.448820

Srinivasan, M. D. and A. (2021). *data.table: Extension of `data.frame`. R package version 1.14.0.* https://cran.r-project.org/package=data.table%0D

Team, R. C. (2021). *R: A language and environment for statistical computing*. R Foundation for Statistical Computing, Vienna, Austria.

Wickham, H. (2007). Reshaping Data with the reshape Package. *Journal of Statistical Software*, *21*(12 SE-Articles), 1–20. https://doi.org/10.18637/jss.v021.i12

Wickham, H. (2021). *tidyr: Tidy Messy Data. R package version 1.1.3*.

Wickham, H., Averick, M., Bryan, J., Chang, W., McGowan, L., François, R., Grolemund, G., Hayes, A., Henry, L., Hester, J., Kuhn, M., Pedersen, T., Miller, E., Bache, S., Müller, K., Ooms, J., Robinson, D., Seidel, D., Spinu, V., & Yutani, H. (2019). Welcome to the Tidyverse. *Journal of Open Source Software*, *4*, 1686. https://doi.org/10.21105/joss.01686

Wu, F., Zhao, S., Yu, B., Chen, Y. M., Wang, W., Song, Z. G., Hu, Y., Tao, Z. W., Tian, J. H., Pei, Y. Y., Yuan, M. L., Zhang, Y. L., Dai, F. H., Liu, Y., Wang, Q. M., Zheng, J. J., Xu, L., Holmes, E. C., & Zhang, Y. Z. (2020). A new coronavirus associated with human respiratory disease in China. *Nature*, *579*(7798), 265–269. https://doi.org/10.1038/S41586-020-2008-3

Yu, G. (2020). Using ggtree to Visualize Data on Tree-Like Structures. *Current Protocols in Bioinformatics*, *69*. https://doi.org/10.1002/cpbi.96